论文部分内容阅读
目的探讨新辅助化疗治疗宫颈癌的临床疗效和预后影响因素。方法 98例宫颈癌患者术前进行新辅助化疗,3个疗程后进行根治性手术治疗,观察患者的肿瘤大小变化、临床疗效和预后相关因素。结果 98例患者中,完全缓解12例,部分缓解63例,总有效率为76.5%。所有患者治疗后肿瘤显著缩小,与治疗前差异有统计学意义(P<0.05)。影响新辅助化疗后宫颈癌患者的预后因素为临床分期、组织学分型、病理分级、肿瘤直径和淋巴结转移。结论新辅助化疗对早期宫颈癌患者具有显著优势,能够明显缩小瘤体,提高手术疗效,值得临床进一步推广。
Objective To investigate the clinical efficacy and prognostic factors of neoadjuvant chemotherapy for cervical cancer. Methods Ninety-eight patients with cervical cancer received neoadjuvant chemotherapy before operation. After three courses of treatment, radical surgery was performed to observe the changes of tumor size, clinical efficacy and prognostic factors. Results In 98 patients, complete remission in 12 cases, partial remission in 63 cases, the total effective rate was 76.5%. The tumor size of all patients was significantly reduced after treatment, with statistical significance before treatment (P <0.05). Prognostic factors affecting cervical cancer patients after neoadjuvant chemotherapy were clinical stage, histological type, pathological grade, tumor diameter and lymph node metastasis. Conclusion Neoadjuvant chemotherapy has obvious advantages for patients with early cervical cancer, can significantly reduce the tumor and improve the curative effect, it is worth further clinical promotion.